Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping.

Health Data Sci · 2022 · PMC9934012 · PMID 36817759

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Most of these findings are in agreement with findings from other studies [ 10 – 14 ] that have not observed highly significant risk association of ACEi or ARB usage on COVID-19 clinical outcomes and suggest that the usage of ACEi or ARB medications can be continued when indicated in patients with COVID-19 [ 10 – 14 , 18 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.